New Products, Continued Operating Efficiency Drive 65% Gross Margin
WESTFORD, Mass., Nov. 1 /PRNewswire-FirstCall/ -- Cynosure, Inc.
(NASDAQ:CYNO), a leading developer and manufacturer of a broad
array of light-based aesthetic treatment systems, today announced
record revenues and net income for the three months ended September
30, 2007. Third Quarter 2007 Financial Results Revenues increased
70% to $31.5 million in the third quarter of 2007, from $18.6
million for the third quarter of 2006. Gross profit margin
increased 510 basis points to 65.0% of total revenues compared with
59.9% for the same period in 2006. Third quarter 2007 net income
was $4.4 million, or $0.34 per diluted share, compared with a net
loss of $4.2 million, or $0.38 per share, in the third quarter of
2006. Results for the 2006 period included a $10 million charge
relating to a royalty settlement. No similar charge was incurred
during the 2007 period. Non-GAAP net income, which excludes
stock-based compensation expense and its related income tax
effects, was $5.1 million, or $0.40 per diluted share, for the
third quarter of 2007. This compares with Non-GAAP net income of
$1.9 million, or $0.16 per diluted share, in the third quarter of
2006, which excludes stock-based compensation expense, the $10
million royalty settlement and their related income tax effects.
Please refer to the financial reconciliations included in this news
release for a reconciliation of GAAP results to Non-GAAP results
for the three months ended September 30, 2007 and 2006. "The
combination of strong demand for our newest aesthetic laser systems
and continued operating efficiency drove record financial results
for Cynosure in the third quarter of 2007," said President and
Chief Executive Officer Michael Davin. "Laser product revenue
increased 74% year-over-year, reflecting the rapid market
penetration of Smartlipo(R), our proprietary LaserBodySculpting(R)
workstation, and Affirm(R), our new multi-energy platform for
anti-aging. Smartlipo is becoming a highly recognized brand in the
emerging laser lipolysis marketplace, and we are supporting the
product platform with a comprehensive training program that now
includes 16 sites in North America. At the same time, Affirm
continues to win accolades from the aesthetic medical community.
"With the launch of our 18-watt Smartlipo at the Plastic Surgery
2007 Meeting, we now have a family of three LaserBodySculpting
products to meet the unique needs of our aesthetic surgical
customer base," Davin said. "Both the 6-watt and 10-watt Smartlipo
workstations are upgradable to the new 18-watt system, which is
designed for dermatologists and plastic surgeons with higher volume
practices. These customers appreciate the ease of use and
efficiency of the new system. It allows them to complete a typical
procedure in about one-third the time as the original Smartlipo,
with the same level of safety and efficacy as the 6-watt and
10-watt versions." During the third quarter, Cynosure announced the
appointment of John F. Lenihan to the new position of Vice
President of International Distribution. Lenihan will manage and
develop Cynosure's international distributor business, focusing on
Europe and the Middle East. Lenihan's appointment was a key
component in Cynosure's effort to broaden its international
distribution, an initiative that included the promotion of Stephen
Lim to head the company's international distribution effort in the
Asia-Pacific region. Lenihan and Lim will report to Kenji Shimizu,
Executive Vice President of International Sales. "International
expansion remains a key strategy for Cynosure, particularly as we
prepare to introduce next generation products and explore new
markets," Davin said. "We want to continue the momentum we have
achieved through our current international alliances." Nine-Month
Results For the nine months ended September 30, 2007, revenues
increased approximately 63% to $87.7 million from $53.8 million for
the same period in 2006. Net income for the first nine months of
2007 was $9.2 million, or $0.73 per diluted share, versus a net
loss of $2.2 million, or $0.20 per share, for the same period in
2006. Non-GAAP net income, which excludes stock-based compensation
expense and its related income tax effects and, for 2006, expenses
relating to the termination of two agreements associated with
Cynosure's legacy relationship with Sona MedSpa International and
the royalty settlement and their related income tax effects, was
$12.4 million, or $0.99 per diluted share, for the first nine
months of 2007 compared with $5.2 million, or $0.42 per diluted
share, for the first nine months of 2006. Please refer to the
financial reconciliations included in this news release for a
reconciliation of GAAP results to Non-GAAP results for the nine
months ended September 30, 2007 and 2006. Business Outlook "Our
commitment to product innovation, physician training and
cutting-edge technology has enabled Cynosure to achieve outstanding
results through the first nine months of 2007, and has put us on
pace to deliver a year of record growth," Davin said. "We are
focused on growing faster than the aesthetic laser market, and our
newest products, including Affirm and Smartlipo, position us to do
just that. They have raised the bar for performance and
satisfaction, opening exciting opportunities to introduce new
generations of these systems and to expand our market share in the
quarters ahead." Use of Non-GAAP Financial Measures To supplement
Cynosure's consolidated financial statements presented in
accordance with GAAP, this press release includes the following
measures defined as non-GAAP financial measures by the SEC:
non-GAAP net income and non-GAAP diluted earnings per share. The
presentation of this financial information is not intended to be
considered in isolation or as a substitute for the financial
information prepared and presented in accordance with GAAP. In
addition, the non-GAAP financial measures included in this press
release may be different from, and therefore not comparable to,
similar measures used by other companies. Although certain non-GAAP
financial measures used in this release exclude the accounting
treatment of stock-based compensation, these non-GAAP measures
should not be relied upon independently, as they ignore the
contribution to our operating results that is generated by the
incentive and compensation effects of the underlying stock-based
compensation programs. For more information on these non-GAAP
financial measures, please see the non-GAAP data included at the
end of this release. This data has more details of the GAAP
financial measures that are most directly comparable to non-GAAP
financial measures and the related reconciliations between these
financial measures. Cynosure's management believes that these
non-GAAP financial measures provide meaningful supplemental
information regarding our performance by excluding certain expenses
and expenditures that may not be indicative of our core business
operating results. Cynosure believes that both management and
investors benefit from referring to these non-GAAP financial
measures in assessing Cynosure's performance and when planning,
forecasting and analyzing future periods. These non-GAAP financial
measures also facilitate management's internal comparisons to
Cynosure's historical performance and our competitors' operating
results. Cynosure believes that these non-GAAP measures are useful
to investors in allowing for greater transparency with respect to
supplemental information used by management in its financial and
operational decision making. Conference Call Cynosure will host a
conference call for investors today at 9:00 a.m. ET. On the call,
Michael Davin and Timothy Baker, the company's executive vice
president and chief financial officer, will discuss the
third-quarter 2007 financial results, provide a business update and
discuss the company's growth strategy. Those who wish to listen to
the conference call webcast should visit the "Investor Relations"
section of the company's website at http://www.cynosure.com/. The
live call also can be accessed by dialing (877) 681-3378 or (719)
325-4802 (confirmation code: 4873934). If you are unable to listen
to the live call, the webcast will be archived on the company's
website. About Cynosure, Inc. Cynosure, Inc. develops and markets
aesthetic treatment systems that are used by physicians and other
practitioners to perform non-invasive and minimally invasive
procedures to remove hair, treat vascular lesions, rejuvenate skin
through the treatment of shallow vascular and pigmented lesions,
laser lipolysis and temporarily reduce the appearance of cellulite.
Cynosure's products include a broad range of laser and other
light-based energy sources, including Alexandrite, pulsed dye,
Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure
was founded in 1991. For corporate or product information, contact
Cynosure at 800-886-2966, or visit http://www.cynosure.com/. Safe
Harbor Any statements in this press release about future
expectations, plans and prospects for Cynosure, Inc., including
statements about the company's expectations and future financial
performance, as well as other statements containing the words
"believes," "anticipates," "plans," "expects," "will" and similar
expressions, constitute forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995.
Actual results may differ materially from those indicated by such
forward-looking statements as a result of various important
factors, including Cynosure's history of operating losses, its
reliance on sole source suppliers, the inability to accurately
predict the timing or outcome of regulatory decisions, changes in
consumer preferences, competition in the aesthetic laser industry,
economic, market, technological and other factors discussed in
Cynosure's most recent Annual Report on Form 10-K, which is filed
with the Securities and Exchange Commission. In addition, the
forward-looking statements included in this press release represent
Cynosure's views as of the date of this press release. Cynosure
anticipates that subsequent events and developments will cause its
views to change. However, while Cynosure may elect to update these
forward- looking statements at some point in the future, it
specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing Cynosure's views as of any date subsequent to the date
of this press release. Scott Solomon Vice President Sharon Merrill
Associates, Inc. 617.542.5300 Consolidated Statements of Income (In
thousands, except per share data) Three Months Nine Months
September 30, September 30, 2007 2006 2007 2006 (unaudited)
(unaudited) Revenues $31,533 $18,556 $87,742 $53,826 Cost of
revenues 11,045 7,442 32,035 23,015 Gross profit 20,488 11,114
55,707 30,811 Operating expenses Selling and marketing 10,310 6,372
29,447 17,979 Research and development 1,468 1,207 4,958 3,455
General and administrative 3,143 2,041 8,371 6,218 Royalty
settlement - 10,000 - 10,000 Total operating expenses 14,921 19,620
42,776 37,652 Income (loss) from operations 5,567 (8,506) 12,931
(6,841) Interest income, net 661 680 1,762 2,063 Other income, net
356 215 440 621 Income (loss) before income taxes 6,584 (7,611)
15,133 (4,157) Income tax provision (benefit) 2,207 (3,370) 5,927
(2,019) Minority interest in net income of subsidiary - 6 - 41 Net
income (loss) $4,377 $(4,247) $9,206 $(2,179) Diluted net income
(loss) per share $0.34 $(0.38) $0.73 $(0.20) Diluted weighted
average shares outstanding 12,751 11,107 12,604 11,061 Basic net
income (loss) per share $0.36 $(0.38) $0.78 $(0.20) Basic weighted
average shares outstanding 12,281 11,107 11,863 11,061 Condensed
Consolidated Balance Sheet (In thousands) September 30, December
31, 2007 2006 (unaudited) Assets: Cash, cash equivalents and
marketable securities $76,963 $57,246 Accounts receivable, net
22,549 19,871 Amounts due from related parties 16 335 Inventories
23,216 17,624 Deferred tax asset, current portion 2,714 2,604
Prepaid expenses and other current assets 2,857 4,977 Total current
assets 128,315 102,657 Property and equipment, net 6,670 5,662
Other noncurrent assets 1,272 1,247 Total assets $136,257 $109,566
Liabilities and stockholders' equity: Accounts payable and accrued
expenses $19,635 $17,063 Amounts due to related parties 2,021 1,052
Short-term loan - 167 Deferred revenue 4,409 3,476 Capital lease
obligations 465 439 Total current liabilities 26,530 22,197 Capital
lease obligations, net of current portion 829 1,069 Deferred
revenue, net of current portion 374 311 Other long-term liabilities
157 119 Total stockholders' equity 108,367 85,870 Total liabilities
and stockholders' equity $136,257 $109,566 To supplement our
consolidated financial statements presented in accordance with
GAAP, Cynosure uses the following measures defined as non- GAAP
financial measures by the SEC: non-GAAP gross profit, non-GAAP
income from operations, non-GAAP net income and non-GAAP diluted
earnings per share. The presentation of this financial information
is not intended to be considered in isolation or as a substitute
for the financial information prepared and presented in accordance
with GAAP. In addition, the non-GAAP financial measures included in
this press release may be different from, and therefore not
comparable to, similar measures used by other companies. Although
certain non-GAAP financial measures used in this release exclude
the accounting treatment of stock-based compensation, these
non-GAAP measures should not be relied upon independently as they
ignore the contribution to our operating results that is generated
by the incentive and compensation effects of the underlying
stock-based compensation programs. Cynosure's management believes
that these non-GAAP financial measures provide meaningful
supplemental information regarding our performance by excluding
certain expenses and expenditures that may not be indicative of our
core business operating results. Cynosure believes that both
management and investors benefit from referring to these non-GAAP
financial measures in assessing Cynosure's performance and when
planning, forecasting and analyzing future periods. These non-GAAP
financial measures also facilitate management's internal
comparisons to Cynosure's historical performance and our
competitors' operating results. Cynosure believes that these
non-GAAP measures are useful to investors in allowing for greater
transparency with respect to supplemental information used by
management in its financial and operational decision making.
Reconciliation of GAAP Income Statement Measures to Non-GAAP Income
Statement Measures (In thousands, except per share data) Three
Months Nine Months September 30 September 30 2007 2006 2007 2006
(unaudited) (unaudited) Gross profit $20,488 $11,114 $55,707
$30,811 Non-GAAP adjustments to gross profit: Stock-based
compensation 100 53 269 79 Sona - inventory writedown - - - 667
Total Non-GAAP adjustments to gross profit 100 53 269 746 Non-GAAP
Gross profit $20,588 $11,167 $55,976 $31,557 Three Months Nine
Months September 30 September 30 2007 2006 2007 2006 (unaudited)
(unaudited) Income (loss) from operations $5,567 $(8,506) $12,931
$(6,841) Non-GAAP adjustments to income (loss) from operations:
Stock-based compensation 1,436 820 4,283 1,611 Sona - inventory
writedown and provision for doubtful account - - - 1,130 Royalty
settlement - 10,000 - 10,000 Total Non-GAAP adjustments to gross
profit 1,436 10,820 4,283 12,741 Non-GAAP Income from operations
$7,003 $2,314 $17,214 $5,900 Three Months Nine Months September 30
September 30 2007 2006 2007 2006 (unaudited) (unaudited) Net income
(loss) $4,377 $(4,247) $9,206 $(2,179) Non-GAAP adjustments to net
income (loss): Stock-based compensation 1,436 820 4,283 1,611 Sona
- inventory writedown and provision for doubtful account - - -
1,130 Royalty settlement - 10,000 - 10,000 Income tax provision
from IRS Audit - - 702 - Income tax effect of non-GAAP adjustments
(680) (4,638) (1,765) (5,410) Total Non-GAAP adjustments to net
income (loss) 756 6,182 3,220 7,331 Non-GAAP Net income $5,133
$1,935 $12,426 $5,152 Three Months Nine Months September 30
September 30 2007 2006 2007 2006 (unaudited) (unaudited) Diluted
net income (loss) per share $0.34 $(0.38) $0.73 $(0.20)
Anti-dilutive impact of higher weighted average shares used to
compute Non-GAAP diluted net income per share - 0.03 - 0.02
Stock-based compensation 0.11 0.07 0.34 0.13 Sona - inventory
writedown and provision for doubtful account - - - 0.09 Royalty
settlement - 0.83 - 0.82 Income tax provision from IRS Audit - -
0.06 - Income tax effect of Non-GAAP adjustments (0.05) (0.38)
(0.14) (0.45) Total Non-GAAP adjustments to net income (loss) 0.06
0.54 0.26 0.62 Non-GAAP Diluted net income per share 0.40 0.16 0.99
0.42 Weighted average shares used to compute diluted net
income(loss) per share 12,751 11,107 12,604 11,061 Weighted average
shares used to compute Non-GAAP diluted net income per share 12,751
12,061 12,604 12,125 DATASOURCE: Cynosure, Inc. CONTACT: Scott
Solomon, Vice President of Sharon Merrill Associates, Inc.,
+1-617-542-5300, , for Cynosure, Inc. Web site:
http://www.cynosure.com/
Copyright
Cynosure (NASDAQ:CYNO)
Historical Stock Chart
From May 2024 to Jun 2024
Cynosure (NASDAQ:CYNO)
Historical Stock Chart
From Jun 2023 to Jun 2024